MX2010004706A - Variantes ingenierizadas de pertactina para uso vacunal. - Google Patents

Variantes ingenierizadas de pertactina para uso vacunal.

Info

Publication number
MX2010004706A
MX2010004706A MX2010004706A MX2010004706A MX2010004706A MX 2010004706 A MX2010004706 A MX 2010004706A MX 2010004706 A MX2010004706 A MX 2010004706A MX 2010004706 A MX2010004706 A MX 2010004706A MX 2010004706 A MX2010004706 A MX 2010004706A
Authority
MX
Mexico
Prior art keywords
engineered
pertactin
vaccines
pertactins
protein
Prior art date
Application number
MX2010004706A
Other languages
English (en)
Inventor
Acosta Anabel Alvarez
Medina Tamara Menendez
Nieto Gerardo Enrique Guillen
Leal Yoelys Cruz
Vazquez Diogenes Quintana
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2010004706A publication Critical patent/MX2010004706A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se enmarca en el campo de la biomedicina, y comprende la ingenierización de la proteína pertactina (Prn) para su obtención y uso en vacunas bacterianas, más particularmente en vacunas acelulares contra Bordetella pertussis; las pertactinas ingenierizadas abarcan en su estructura el polimorfismo de diferentes cepas, y al ensayarse como vacunas inducen una respuesta de anticuerpos de mayor capacidad protectora y de mayor actividad opsonofagocítica; las variantes ingenierizadas de pertactina de esta invención son aplicables en la medicina humana y veterinaria.
MX2010004706A 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal. MX2010004706A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal
PCT/CU2008/000009 WO2009056076A1 (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal

Publications (1)

Publication Number Publication Date
MX2010004706A true MX2010004706A (es) 2010-05-27

Family

ID=40473455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004706A MX2010004706A (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal.

Country Status (11)

Country Link
US (2) US8569470B2 (es)
EP (1) EP2216045A1 (es)
KR (1) KR20100093548A (es)
CN (1) CN101878038B (es)
AR (1) AR069086A1 (es)
BR (1) BRPI0817898A2 (es)
CA (1) CA2702697A1 (es)
CU (1) CU23679A1 (es)
MX (1) MX2010004706A (es)
RU (1) RU2499046C2 (es)
WO (1) WO2009056076A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133734T2 (de) * 2000-05-25 2009-05-14 Institut Pasteur Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen
EP1174505A1 (en) 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
WO2005032584A2 (en) * 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
UA40596U (ru) * 2006-05-16 2009-04-27 Институт Проблем Безопасности Атомных Электростанций Национальной Академии Наук Украины Энергоблок атомной электростанции

Also Published As

Publication number Publication date
RU2010121646A (ru) 2011-12-10
KR20100093548A (ko) 2010-08-25
AR069086A1 (es) 2009-12-30
CN101878038B (zh) 2013-11-06
CU23679A1 (es) 2011-07-11
EP2216045A1 (en) 2010-08-11
CN101878038A (zh) 2010-11-03
RU2499046C2 (ru) 2013-11-20
CA2702697A1 (en) 2009-05-07
US20110070265A1 (en) 2011-03-24
WO2009056076A1 (es) 2009-05-07
BRPI0817898A2 (pt) 2015-05-05
US20140011216A1 (en) 2014-01-09
US8569470B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
IN2015DN02729A (es)
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MY158992A (en) Forms of rifaximin and uses thereof
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
CY1119382T1 (el) Φυσικα βλαστοκυτταρα γελης toy wharton και καθαρισμος αυτων
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
MY156286A (en) Human il-23 antigen binding proteins
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
WO2006014292A3 (en) Oral vaccine for borrelia
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2010053610A3 (en) Stable anthrax vaccine formulations
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
MY160298A (en) Glycols as pathogen inactivating agents
BR112014014319A2 (pt) composições de cuidado oral
CL2011000913A1 (es) Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.
IN2015MN00038A (es)
JP2013523886A5 (es)
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Legal Events

Date Code Title Description
FG Grant or registration